<DOC>
	<DOCNO>NCT02027116</DOCNO>
	<brief_summary>To evaluate safety , tolerability immunogenicity VGX-6150 second-line therapy chronic hepatitis C patient</brief_summary>
	<brief_title>Phase I Trial Evaluate Safety , Tolerability Immunogenicity VGX-6150 Second-line Therapy Chronic Hepatitis C Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Subjects want participate trial meet follow criterion . 1 . Male female age 19 65 year 2 . Chronic hepatitis C patient infect HCV genotype 1a 1b 3 . Patients failed* SOC therapy PEGIFN ribavirin triple therapy SOC DAA agent *Treatment failure define follow ; A . Partial response ( PR ) Serum HCV RNA level decline least 2 log10 still detect treatment week 24 B. Nonresponse ( NR ) Serum HCV RNA level decline least 2 log10 treatment week 12 C. Relapse Serum HCV RNA undetected treatment detectable end treatment D. Treatment discontinuation due ADR reason 4 . Patients whose deltoid muscle ( left right ) accessible 12 19 mm cannula/ electrode intramuscular ( IM ) injection electroporation ( EP ) 5 . Patients comply plan schedule protocol 6 . Patients give write informed consent voluntarily Subjects meet following participate study . 1 . Liver transplant recipient 2 . Patients decompensated liver cirrhosis history evidence ascites , esophageal variceal hemorrhage and/or hepatic encephalopathy 3 . Malignant tumor patient receive radiotherapy chemotherapy study participation 4 . Current active infection except hepatitis C require medical treatment 5 . Autoimmune disease patient immunodeficient ( immunocompromised ) patient 6 . Patients receive immunomodulators , cytotoxic agent systemic corticosteroid chronic disease hepatitis C within 2 month study participation 7 . Patients receive nonsteroidal antiinflammatory drug ( NSAIDs ) within 10 day IP administration 8 . Concomitant disease judge unacceptable study participation investigator ( e.g. , severe cardiovascular , renal , psychiatric disease ) 9 . Clinically significant abnormal finding physical examination , laboratory test , vital sign ECG investigator 's discretion 10 . Patients implantable pacemaker 11 . Patients metal implant IP administration area nearby 12 . Positive HBsAg , HIV Ab 13 . Previous history gene therapy 14 . History allergy anaphylaxis component IP vaccine 15 . Patients receive major surgery within 4 week IP administration 16 . Blood transfusion within 4 week IP administration 17 . Current alcohol drug abuse 18 . Patients receive vaccine within 30 day IP administration 19 . Pregnancy breastfeed woman 20 . Women childbearing potential ( WOCBP ) men partner WOCBP unwilling use adequate contraception abstinent trial 21 . Patients receive investigational product within 30 day study participation 22 . Patients incapable participate trial investigator 's judgment</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>chronic hepatitis C</keyword>
	<keyword>DNA Vaccine</keyword>
	<keyword>Electroporation</keyword>
	<keyword>Intramuscular ( IM ) Injection</keyword>
</DOC>